SynthesisThe Cochrane database of systematic reviews2000
Antidepressants for smoking cessation.
Synthesis in The Cochrane database of systematic reviews, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Trial Comparing Different Methods of Support With Stopping Smoking Offered Through The National Health Service (NHS) Smoking Helpline
The STOP Study: Real World Effectiveness of Zyban Treatment in a Clinical Population
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Community interventions for reducing smoking among adults.The Cochrane database of systematic reviews · 2002Pooled it
- A contingency-management intervention to promote initial smoking cessation among opioid-maintained patients.Experimental and clinical psychopharmacology · 2010Trial
- Protocol for the Proactive Or Reactive Telephone Smoking CeSsation Support (PORTSSS) trial.Trials · 2009Trial
- Psychological mediators of bupropion sustained-release treatment for smoking cessation.Addiction (Abingdon, England) · 2008Trial
- Efficacy of confrontational counselling for smoking cessation in smokers with previously undiagnosed mild to moderate airflow limitation: study protocol of a randomized controlled trial.BMC public health · 2007Trial
- Pharmacokinetics of Dual Amino Acids for Dry Powder Inhalation Therapy in Pulmonary Drug Delivery: An In-Vivo Study.Addiction & health · 2025Article
- Contingency management for behavior change: applications to promote brief smoking cessation among opioid-maintained patients.Experimental and clinical psychopharmacology · 2011Article
- Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis.Trends in pharmacological sciences · 2010Review
- Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.PharmacoEconomics · 2010Review
- Attention bias in nicotine withdrawal and under stress.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2009Article
- Tobacco addiction.Lancet (London, England) · 2008Review
- Motivational interviewing for smokers.The British journal of general practice : the journal of the Royal College of General Practitioners · 2007Article
- Medication screening for smoking cessation: a proposal for new methodologies.Psychopharmacology · 2006Review
- Management of Abdominal Aortic Aneurysms.Current treatment options in cardiovascular medicine · 2005Article
- Determinants for successful smoking cessation with bupropion in daily practice.Pharmacy world & science : PWS · 2003Article
- Nicotinic acetylcholine receptors as targets for antidepressants.Molecular psychiatry · 2002Review
Corrections and comments
- Updated by
- Update of
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere are two reasons to believe antidepressants might help in smoking cessation. First, depression may be a symptom of nicotine withdrawal, and smoking cessation sometimes precipitates depression. Second, smoking appears to be due, in part, to deficits in dopamine, serotonin and norepinephrine, all of which are increased by antidepressants.
objectivesThe aim of this review is to assess the effectiveness of antidepressant medications in aiding long term smoking cessation. The drugs include bupropion; doxepin; fluoxetine; imipramine; moclobemide; nortriptyline; selegiline; sertraline, tryptophan and venlafaxine. SEARCH STRATEGY: We searched the Cochrane Tobacco Addiction Group trials register which includes trials indexed in Medline, Embase, SciSearch and PsycLit, and other reviews and meeting abstracts. SELECTION CRITERIA: We considered randomized trials comparing antidepressant drugs to placebo or an alternative therapeutic control for smoking cessation. We excluded trials with less than 6 months follow-up. DATA COLLECTION AND ANALYSIS: We extracted data in duplicate on the type of study population, the nature of the drug therapy, the outcome measures, method of randomisation, and completeness of follow-up. The main outcome measure was abstinence from smoking after at least six months follow-up in patients smoking at baseline. We used the most rigorous definition of abstinence for each trial, and biochemically validated rates if available. Where appropriate, we performed meta-analysis using a fixed effects model. MAIN
resultsThere was one trial each of moclobemide, sertraline and venlafaxine, two of fluoxetine and nortriptyline, and five trials of bupropion, one of which tested long term use to prevent relapse. Nortriptyline and bupropion both increased cessation. In one trial the combination of bupropion and nicotine patch produced higher quit rates than patch alone. REVIEWER'S
conclusionsSome antidepressants (bupropion and nortriptyline) can aid smoking cessation. It is not clear whether these effects are specific for individual drugs, or a class effect.
Indexed as
Identifiers
11034670What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.